Document Detail

Molecular virology of hepatitis C virus (HCV): 2006 update.
Jump to Full Text
MedLine Citation:
PMID:  16614739     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Fascinating progress in the understanding of the molecular biology of hepatitis C virus (HCV) was achieved recently. The replicon system revolutionized the investigation of HCV RNA replication and facilitated drug discovery. Novel systems for functional analyses of the HCV glycoproteins allowed the validation of HCV receptor candidates and the investigation of cell entry mechanisms. Most recently, recombinant infectious HCV could be produced in cell culture, rendering all steps of the viral life cycle, including entry and release of viral particles, amenable to systematic analysis. In this review, we summarize recent advances and discuss future research directions.
Volker Brass; Darius Moradpour; Hubert E Blum
Related Documents :
10866369 - Hepatitis c viral ires inhibition by phenazine and phenazine-like molecules.
20932139 - Advances and challenges in studying hepatitis c virus in its native environment.
25213209 - First detection of hepatitis e virus in central argentina: environmental and serologica...
25389779 - Performance of two hcv rna assays during protease inhibitor-based triple therapy in pat...
21903989 - Effect of dialysis modality on survival of hepatitis c-infected esrf patients.
25292029 - Comparison of viral hepatitis-associated hepatocellular carcinoma due to hbv and hcv - ...
22171239 - Switching antiretroviral therapy to minimize metabolic complications.
19881229 - Standardized prevalence ratios for chronic hepatitis c virus infection among adult japa...
18774889 - The diffusion of a community-level hiv intervention for women: lessons learned and best...
Publication Detail:
Type:  Journal Article     Date:  2006-04-01
Journal Detail:
Title:  International journal of medical sciences     Volume:  3     ISSN:  1449-1907     ISO Abbreviation:  Int J Med Sci     Publication Date:  2006  
Date Detail:
Created Date:  2006-04-14     Completed Date:  2007-06-12     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  101213954     Medline TA:  Int J Med Sci     Country:  Unknown    
Other Details:
Languages:  eng     Pagination:  29-34     Citation Subset:  -    
Department of Medicine II, University of Freiburg, D-79106 Freiburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Int J Med Sci
Journal ID (publisher-id): ijms
ISSN: 1449-1907
Publisher: Ivyspring International Publisher, Sydney
Article Information
Download PDF
? Ivyspring International Publisher. This is an open access article. Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited.
Received Day: 30 Month: 12 Year: 2005
Accepted Day: 10 Month: 3 Year: 2006
collection publication date: Year: 2006
Electronic publication date: Day: 1 Month: 4 Year: 2006
Volume: 3 Issue: 2
First Page: 29 Last Page: 34
ID: 1415840
PubMed Id: 16614739
Publisher Id: ijmsv03p0029

Molecular Virology of Hepatitis C Virus (HCV): 2006 Update
Volker Brass1
Darius Moradpour2
Hubert E. Blum1
1. Department of Medicine II, University of Freiburg, D-79106 Freiburg, Germany
2. Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH-1011 Lausanne, Switzerland
Correspondence: Corresponding address: Hubert E. Blum, M.D., Department of Medicine II, University of Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel. +49 761 270 3403. Fax +49 761 270 3610. E-mail:
[conflict] Conflict of interest: The authors have declared that no conflict of interest exists.

1. Introduction

The hepatitis C virus (HCV) belongs to the Flaviviridae family and is the only member of the Hepacivirus genus. HCV infection is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) worldwide 1. Therapeutic options are improving but are still limited and a protective vaccine is not available to date. In 50% to 80% acute HCV infection persists and 4% to 20% of patients with chronic hepatitis C will develop liver cirrhosis within 20 years. In patients with liver cirrhosis, the risk to develop HCC is 1-5% per year. Current standard therapy is the combination of pegylated interferon-? (PEG-IFN-?) and ribavirin. Depending on the HCV genotype and other factors, this strategy results in a sustained virologic response in 50-80% of patients 2-5. However, many patients do not qualify for or do not tolerate standard therapy 6. Therefore, more effective and better tolerated therapeutic strategies are urgently needed. The development of such strategies depends on a detailed understanding of the molecular virology of HCV infection.

The investigation of the HCV life cycle and pathogenesis has been complicated by the lack of efficient cell culture systems and small animal models. Nevertheless, significant progress could be made using heterologous expression systems, functional cDNA clones 7, the replicon system 8, 9, and functional HCV pseudoparticles 10, 11 (see refs. 12-14 for reviews). Most recently, a major milestone was the production of recombinant infectious HCV particles in cell culture 15-17. The model systems, summarized in Table 1, are the current basis for the study of the HCV life cycle and the development of novel antiviral strategies.

2. The replicon system

For many years, HCV research was hampered by the extremely restricted host range and the inefficiency of in vitro models based on the incubation of cells in culture with HCV particles. Therefore, the establishment of a replicon system for HCV was a milestone in HCV research 8, 18. The prototype subgenomic replicon utilized a particular HCV genotype 1b clone termed Con1. In this system, the structural region was replaced by the sequence encoding the neomycin phosphotransferase gene resulting in G418 resistance. Expression of the nonstructural proteins is directed by a heterologous encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) downstream of the neomycin phosphotransferase gene. After transfection into the human HCC cell line Huh-7 G418 resistant colonies contain self-replicating HCV RNA. Critical for the usefulness of this system was the identification of specific amino acid substitutions, i.e., cell culture-adaptive changes, that increased the efficiency of replication initiation by several orders of magnitude 9. With the replicon system it became possible, for the first time, to study efficient and genuine HCV RNA replication in vitro as well as structural aspects of the replication complex, basic replication processes, virus-host cell interactions, and antiviral agents.

In the last 6 years, a large panel of different replicon systems has been developed (Fig. 2). These include replicons from genotype 1a 19 and 2a 20, transient systems expressing easily quantifiable marker enzymes 21, replicons with green fluorescent protein (GFP) insertions in NS5A to track replication complexes in living cells 22, and full length replicons. In addition, the spectrum of permissive host cells has been expanded 23.

The replicon system revolutionized the research on basic replication processes. However, the step of infection and entry as well as the release of viral progeny could not be analysed to date. Wakita and colleagues, however, generated a genotype 2a replicon (JFH-1) that was isolated from the serum of a patient with fulminant hepatitis C 20. This system turned out to replicate very efficiently in different cell types. Furthermore, the full-length JFH-1 sequence produced infectious viral particles that could be passaged in cell culture 15, 17. Further, chimeric constructs with the structural region of the J6 genotype 2a clone improved the infectivity of this system significantly 16. This recombinant infectious HCV cell culture system represents the last major milestone in the field and renders the complete viral life cycle accessible to detailed analysis in vitro.

3. Cell entry

Surrogate models for the study of the early steps of viral life cycle have been established, including infectious retroviral pseudotypes displaying functional HCV glycoproteins. These pseudotypes turned out to provide a robust model system for the study of viral entry 10, 11. HCV pseudoparticle infectivity is pH-dependent and restricted primarily to human hepatocytes and hepatocyte-derived cell lines. Thus, HCV entry likely involves transit through an endosomal, low pH compartment and fusion with the endosomal membrane.

HCV E2 binds with high affinity to the large external loop of CD81, a tetraspanin found on the surface of many cell types including hepatocytes 24. However, CD81 is not sufficient to mediate cell entry and several cofactors appear to be required. The low density lipoprotein receptor (LDLR) 25 and scavenger receptor class B type I (SR-BI) 26 have, among others, been proposed as components of a putative HCV receptor complex. The concept, that lipoproteins could play an important role for cell entry is supported by recent data from studies on HCV pseudotypes that demonstrate an enhancement of infectivity by certain components of human serum 27, 28. In particular, association to high density lipoprotein (HDL) seems to enhance SR-BI guided cell entry and could protect viral particles from neutralizing antibodies 29.

4. Translation and polyprotein processing

The HCV genome consists of a 9.6-kb positive-strand RNA that comprises a long open reading frame flanked by 5' and 3' noncoding regions (NCR). The 5' NCR is highly conserved among different HCV isolates and contains an IRES. The IRES directly binds the 40S ribosomal subunit independently of the pre-initiation factors necessary for cap-dependent translation. The three-dimensional structure of the HCV IRES bound to the 40S ribosomal subunit illustrates the molecular basis of this cap-independent translation process 30. High-resolution structural data on critical elements of the IRES and detailed characterization of the translation initiation complex further improves the view on the HCV translation initiation 31, 32.

Translation of the HCV genome leads to a polyprotein precursor that is co- and post-translationally processed by cellular and viral proteases to produce the mature structural and nonstructural proteins. The N-terminal one-third of the polyprotein harbors the structural proteins core, E1 and E2 that form the viral particle. The structural region is followed by the p7 polypeptide which may be involved in ion channel formation (see below). The nonstructural proteins 2-5B coordinate viral replication by the formation of a membrane-bound replication complex. Processing of the polyprotein at the core/E1, E1/E2, E2/p7, and p7/NS2 sites by the host cell signal peptidase produces all structural proteins and p7. Two viral proteases are responsible for the maturation of the nonstructural proteins. The NS2-3 autoprotease cleaves at the NS2/NS3 junction while all downstream sites are processed by the NS3-4A serine protease.

5. Molecular aspects of viral proteins
5.1 Structural proteins
5.1.1 Core protein

The HCV core protein is a highly basic, RNA-binding protein which presumably forms the viral nucleocapsid. Of note, the core protein has been reported to interact with numerous cellular proteins and to affect host cell functions such as gene transcription, lipid metabolism, apoptosis and various signaling pathways 33. Further, it has been associated with the induction of steatosis and HCC 34-36.

5.1.2 Envelope glycoproteins

The envelope glycoproteins E1 and E2 are type I transmembrane proteins with C-terminal hydrophobic anchors. The ectodomains translocate to the ER lumen where they are modified by extensive N-linked glycosylation. E1 and E2 form non-covalent heterodimers which are believed to represent the building blocks for the viral envelope. The processes of particle assembly and release are poorly understood and have only recently become amenable to systematic investigation. In this context, structural studies on recombinant HCV particles confirmed earlier electron microscopy observations 15.

5.2 ARFP/F protein

The synthesis of a protein encoded by an alternative reading frame within the core region was reported by several groups 37. It was designated ARFP (alternative reading frame protein) or F (frameshift) protein and comprises up to 160 amino acids. The ARFP/F protein is dispensable for HCV RNA replication. Whether it is expressed during natural HCV infection has still to be clarified.

5.3 p7

p7 is a 63-amino acid polypeptide located at the junction between the structural and nonstructural region. It is unknown whether p7 is packaged into viral particles. It is composed of two transmembrane domains and has recently been reported to form hexamers with ion channel activity 38, 39. It is believed that p7 could be important for viral assembly because the corresponding protein of the related bovine viral diarrhea virus (BVDV) is essential for the production of infectious progeny virus but not for RNA replication 40.

5.4 Nonstructural proteins
5.4.1 NS2-3 autoprotease

The NS2/3 junction is cleaved by a remarkable autoprotease consisting of NS2 and the N-terminal third of NS3. Although NS2-3 protease activity is required for the replication in vivo, it is dispensable for replication of subgenomic replicons in vitro. It is unclear whether NS2 fulfills any further functions after separation from NS3.

5.4.2 NS3-4A

NS3 is a multifunctional protein because it harbors a serine protease located in the N-terminal one-third that is responsible for the downstream cleavage in the nonstructural region and a NTPase/RNA helicase domain in the C-terminal two-thirds. NS4A, a 54-amino acid polypeptide, targets NS3 to intracellular membranes and is required as a cofactor for the NS3 serine protease. The crystal structure of the NS3-4A complex revealed that NS4A is an integral component of the enzyme core 41. Surprisingly, the NS3 serine protease recently turned out to influence the innate cellular host defense by inhibition of RIG-I and TLR3 signalling 42, 43. This observation renders the NS3 protease particularly attractive as an antiviral target 44. Serine protease inhibitors have emerged as extremely efficient antiviral components in first 'proof-of-principle' studies in patients with chronic hepatitis C 45, 46.

The enzymatic activity of the NS3 NTPase/helicase activity is indispensable for RNA replication. Putative functions during replication could be to unwind replicative double strand RNA intermediates, to eliminate RNA secondary structures or to separate the genome from nucleic acid binding proteins. Recent advances in the understanding of the molecular mechanisms of this enzyme could enable a specific inhibition as a novel antiviral strategy 47, 48.

5.4.3 NS4B

Due to its very hydrophobic properties, NS4B belongs to the difficult-to-study HCV proteins that are poorly understood. So far, it is known that NS4B is a 27-kDa integral membrane protein that localizes to an ER-derived membranous compartment 49. Interestingly, the expression of NS4B induces a specific membrane alteration, designated as membranous web, that serves as a scaffold for the formation of the viral replication complex 50, 51.

5.4.4 NS5A

NS5A is a phosphorylated zinc metalloprotein of unknown function. Numerous potential functions and a huge list of interaction partners have been described 33. However, suprisingly little efforts has been devoted to a rigorous biochemical characterization of this protein and its definitive role in viral replication remains elusive. NS5A has initially attracted considerable interest because of its potential role in modulating the IFN response (reviewed in ref. 52). These findings are still controversial, however. A striking observation was the concentration of cell culture adaptive replicon mutations within the central part of NS5A 9, 53. Considering the fact that NS5A phosphorylation has an impact on replication efficiency, these observations support the concept that NS5A plays an important role in the regulation of viral replication 54-56. The membrane association of NS5A is mediated by a unique amphipathic alpha-helix which is localized at the N-terminus 57, 58. Limited proteolysis experiments recently allowed the definition of three protein domains within the cytosolic domain 59. More recently, the three-dimensional structure of the N-terminal domain I could be resolved by crystallography. After dimerization, it forms a basic groove facing the cytosol at the surface of the membrane 60. This 'claw like' structure is believed to provide an RNA binding site that could be involved in regulated genome targeting within the replication complex.

5.4.5 NS5B

The key enzyme of the replicase that promotes synthesis of new RNA genomes is the NS5B RNA-dependent RNA polymerase (RdRp). NS5B is a tail-anchored protein, characterized by a transmembrane domain at the C-terminus of the protein responsible for posttranslational membrane targeting 61-63. The structural organization of NS5B is a typical 'right hand' polymerase shape with finger, palm, and thumb subdomains surrounding a completely encircled active site 64. Replication proceeds via synthesis of a complementary minus-strand RNA using the genome as a template and the subsequent synthesis of genomic plus-strand RNA from this minus-strand RNA intermediate. As central component of the HCV replicase, NS5B has emerged as a major target for antiviral intervention 44.

6. RNA replication

As in all positive-strand RNA viruses investigated thus far (reviewed in ref. 65), HCV forms a membrane-associated replication complex, composed of viral proteins, replicating RNA, altered cellular membranes and additional host cell factors 50, 51. A specific membrane alteration, referred to as the membranous web, was recently identified as the site of RNA replication in Huh-7 cells harboring subgenomic HCV replicons 51. Thus, intracellular membranes play a crucial role in HCV replication. Recent data underline the importance of a specific lipid environment for HCV RNA replication 66, 67.

In addition to coordinated protein-protein and protein-membrane interaction, essential cis-acting replication elements (CRE) of the RNA genome were recently discovered. For instance, the sequence coding for the C-terminal domain of NS5B consists of an essential stem-loop, designated SL3.2, within a larger cruciform RNA element, designated SL3 68. Detailed characterization of the SL3.2 domain indicated a functionally important kissing loop interaction with the 3' NCR 69.

Several host cell factors, including hVAP-A, FBL2 or cyclophylin B that influence HCV RNA replication via interaction with different viral proteins have been identified 54, 70, 71. However, the regulation of replication, the switch to translation or assembly and the release of viral particles are still poorly understood.

7. Future research directions

The pace of research in the HCV field has increased enormously with the establishment of the replicon system. The infectious JFH-1 cell culture system promises exiting progress in the understanding of steps in the viral life cycle that have been difficult to study thus far. In particular, HCV entry, cytoplasmic release and uncoating, the initial steps of replication, virus assembly, the release of viral progeny, and the detailed virion structure will be characterized in the infectious cell culture system. Furthermore, the impact of viral proteins such as p7 and NS2 for viral particle formation and possibly of NS5A for the switch between replication and assembly can be explored in this context. New insights into the molecular virology of HCV should identify novel targets for antiviral strategies.

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)Gastroenterology 2002;123:2082–99. [pmid: 12454863]
2. Manns, MP. McHutchison, JG. Gordon, SC. Rustgi, VK. Shiffman, M. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet 2001;358:958–65. [pmid: 11583749]
3. Fried, MW. Shiffman, ML. Reddy, KR. Smith, C. Marinos, G. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med 2002;347:975–82. [pmid: 12324553]
4. Hadziyannis, SJ. Sette, HJr. Morgan, TR. Balan, V. Diago, M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med 2004;140:346–55. [pmid: 14996676]
5. Muir, AJ. Bornstein, JD. Killenberg, PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whitesN Engl J Med 2004;350:2265–71. [pmid: 15163776]
6. Falck-Ytter, Y. Kale, H. Mullen, KD. Sarbah, SA. Sorescu, L. Surprisingly small effect of antiviral treatment in patients with hepatitis CAnn Intern Med 2002;136:288–92. [pmid: 11848726]
7. Kolykhalov, AA. Agapov, EV. Blight, KJ. Mihalik, K. Feinstone, SM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNAScience 1997;277:570–4. [pmid: 9228008]
8. Lohmann, V. Korner, F. Koch, J. Herian, U. Theilmann, L. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell lineScience 1999;285:110–3. [pmid: 10390360]
9. Blight, KJ. Kolykhalov, AA. Rice, CM. Efficient initiation of HCV RNA replication in cell cultureScience 2000;290:1972–4. [pmid: 11110665]
10. Bartosch, B. Dubuisson, J. Cosset, FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexesJ Exp Med 2003;197:633–42. [pmid: 12615904]
11. Hsu, M. Zhang, J. Flint, M. Logvinoff, C. Cheng-Mayer, C. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particlesProc Natl Acad Sci U S A 2003;100:7271–6. [pmid: 12761383]
12. Bartenschlager, R. Frese, M. Pietschmann, T. Novel insights into hepatitis C virus replication and persistenceAdv Virus Res 2004;63:71–180. [pmid: 15530561]
13. Penin, F. Dubuisson, J. Rey, FA. Moradpour, D. Pawlotsky, JM. Structural biology of hepatitis C virusHepatology 2004;39:5–19. [pmid: 14752815]
14. Lindenbach, BD. Rice, C. Unravelling hepatitis C virus replication from genome to functionNature 2005;436:933–938. [pmid: 16107832]
15. Wakita, T. Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Med 2005;11:791–96. [pmid: 15951748]
16. Lindenbach, BD. Evans, MJ. Syder, AJ. Wolk, B. Tellinghuisen, TL. Complete replication of hepatitis C virus in cell cultureScience 2005;309:623–26. [pmid: 15947137]
17. Zhong, J. Gastaminza, P. Cheng, G. Kapadia, S. Kato, T. Robust hepatitis C virus infection in vitro. Proc Natl Acad SciUSA 2005;102:9294–99.
18. Bartenschlager, R. The hepatitis C virus replicon system: from basic research to clinical applicationJ Hepatol 2005;43:210–6. [pmid: 15964655]
19. Blight, KJ. McKeating, JA. Marcotrigiano, J. Rice, CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell cultureJ Virol 2003;77:3181–90. [pmid: 12584342]
20. Kato, T. Date, T. Miyamoto, M. Furusaka, A. Tokushige, K. Efficient replication of the genotype 2a hepatitis C virus subgenomic repliconGastroenterology 2003;125:1808–17. [pmid: 14724833]
21. Krieger, N. Lohmann, V. Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutationsJ Virol 2001;75:4614–24. [pmid: 11312331]
22. Moradpour, D. Evans, MJ. Gosert, R. Yuan, Z. Blum, HE. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexesJ Virol 2004;78:7400–9. [pmid: 15220413]
23. Zhu, Q. Guo, JT. Seeger, C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cellsJ Virol 2003;77:9204–10. [pmid: 12915536]
24. Pileri, P. Uematsu, Y. Campagnoli, S. Galli, G. Falugi, F. Binding of hepatitis C virus to CD81Science 1998;282:938–41. [pmid: 9794763]
25. Agnello, V. Abel, G. Elfahal, M. Knight, GB. Zhang, QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptorProc Natl Acad Sci U S A 1999;96:12766–71. [pmid: 10535997]
26. Scarselli, E. Ansuini, H. Cerino, R. Roccasecca, RM. Acali, S. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virusEmbo J 2002;21:5017–25. [pmid: 12356718]
27. Meunier, JC. Engle, RE. Faulk, K. Zhao, M. Bartosch, B. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1Proc Natl Acad Sci U S A 2005;102:4560–5. [pmid: 15767578]
28. Lavillette, D. Morice, Y. Germanidis, G. Donot, P. Soulier, A. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infectionJ Virol 2005;79:6023–34. [pmid: 15857988]
29. Bartosch, B. Verney, G. Dreux, M. Donot, P. Morice, Y. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodiesJ Virol 2005;79:8217–29. [pmid: 15956567]
30. Spahn C, M. Kieft, JS. Grassucci, RA. Penczek, PA. Zhou, K. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunitScience 2001;291:1959–62. [pmid: 11239155]
31. Kieft, JS. Zhou, K. Grech, A. Jubin, R. Doudna, JA. Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiationNat Struct Biol 2002;9:370–4. [pmid: 11927953]
32. Otto, GA. Puglisi, JD. The pathway of HCV IRES-mediated translation initiationCell 2004;119:369–80. [pmid: 15507208]
33. Tellinghuisen, TL. Rice, CM. Interaction between hepatitis C virus proteins and host cell factorsCurr Opin Microbiol 2002;5:419–27. [pmid: 12160863]
34. Moriya, K. Fujie, H. Shintani, Y. Yotsuyanagi, H. Tsutsumi, T. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic miceNat Med 1998;4:1065–7. [pmid: 9734402]
35. Hope, RG. Murphy, DJ. McLauchlan, J. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteinsJ Biol Chem 2002;277:4261–70. [pmid: 11706032]
36. Lerat, H. Honda, M. Beard, MR. Loesch, K. Sun, J. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virusGastroenterology 2002;122:352–65. [pmid: 11832450]
37. Branch, AD. Stump, DD. Gutierrez, JA. Eng, F. Walewski, JL. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and othersSemin Liver Dis 2005;25:105–17. [pmid: 15732002]
38. Griffin, SD. Beales, LP. Clarke, DS. Worsfold, O. Evans, SD. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, AmantadineFEBS Lett 2003;535:34–8. [pmid: 12560074]
39. Pavlovic, D. Neville, DC. Argaud, O. Blumberg, B. Dwek, RA. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivativesProc Natl Acad Sci U S A 2003;100:6104–8. [pmid: 12719519]
40. Harada, T. Tautz, N. Thiel, HJ. E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studiesJ Virol 2000;74:9498–506. [pmid: 11000219]
41. Kim, JL. Morgenstern, KA. Lin, C. Fox, T. Dwyer, MD. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptideCell 1996;87:343–55. [pmid: 8861917]
42. Gale, MJr. Foy, EM. Evasion of intracellular host defence by hepatitis C virusNature 2005;436:939–45. [pmid: 16107833]
43. Melyan, E. Curran, J. Hofmann, K. Moradpour, D. Binder, M. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature 2005;437:1167–1172. [pmid: 16177806]
44. De Francesco, R. Migliaccio, G. Challenges and successes in developing new therapies for hepatitis CNature 2005;436:953–60. [pmid: 16107835]
45. Lamarre, D. Anderson, PC. Bailey, M. Beaulieu, P. Bolger, G. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature 2003;426:186–9. [pmid: 14578911]
46. Hinrichsen, H. Benhamou, Y. Wedemeyer, H. Reiser, M. Sentjens, RE. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patientsGastroenterology 2004;127:1347–55. [pmid: 15521004]
47. Serebrov, V. Pyle, AM. Periodic cycles of RNA unwinding and pausing by hepatitis C virus NS3 helicaseNature 2004;430:476–80. [pmid: 15269774]
48. Levin, MK. Gurjar, M. Patel, SS. A Brownian motor mechanism of translocation and strand separation by hepatitis C virus helicaseNat Struct Mol Biol 2005;12:429–35. [pmid: 15806107]
49. Hugle, T. Fehrmann, F. Bieck, E. Kohara, M. Krausslich, HG. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane proteinVirology 2001;284:70–81. [pmid: 11352669]
50. Egger, D. Wolk, B. Gosert, R. Bianchi, L. Blum, HE. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complexJ Virol 2002;76:5974–84. [pmid: 12021330]
51. Gosert, R. Egger, D. Lohmann, V. Bartenschlager, R. Blum, HE. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic repliconsJ Virol 2003;77:5487–92. [pmid: 12692249]
52. Tan, SL. Katze, MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5AVirology 2001;284:1–12. [pmid: 11352662]
53. Lohmann, V. Korner, F. Dobierzewska, A. Bartenschlager, R. Mutations in hepatitis C virus RNAs conferring cell culture adaptationJ Virol 2001;75:1437–49. [pmid: 11152517]
54. Evans, MJ. Rice, CM. Goff, SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replicationProc Natl Acad Sci U S A 2004;101:13038–43. [pmid: 15326295]
55. Appel, N. Pietschmann, T. Bartenschlager, R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domainJ Virol 2005;79:3187–94. [pmid: 15709040]
56. Neddermann, P. Quintavalle, M. Di Pietro, C. Clementi, A. Cerretani, M. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell cultureJ Virol 2004;78:13306–14. [pmid: 15542681]
57. Brass, V. Bieck, E. Montserret, R. Wolk, B. Hellings, JA. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5AJ Biol Chem 2002;277:8130–9. [pmid: 11744739]
58. Penin, F. Brass, V. Appel, N. Ramboarina, S. Montserret, R. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5AJ Biol Chem 2004;279:40835–43. [pmid: 15247283]
59. Tellinghuisen, TL. Marcotrigiano, J. Gorbalenya, AE. Rice, CM. The NS5A protein of hepatitis C virus is a zinc metalloproteinJ Biol Chem 2004;279:48576–87. [pmid: 15339921]
60. Tellinghuisen, TL. Marcotrigiano, J. Rice, CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicaseNature 2005;435:374–9. [pmid: 15902263]
61. Schmidt-Mende, J. Bieck, E. Hugle, T. Penin, F. Rice, CM. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymeraseJ Biol Chem 2001;276:44052–63. [pmid: 11557752]
62. Ivashkina, N. Wolk, B. Lohmann, V. Bartenschlager, R. Blum, HE. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segmentJ Virol 2002;76:13088–93. [pmid: 12438637]
63. Moradpour, D. Brass, V. Bieck, E. Friebe, P. Gosert, R. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replicationJ Virol 2004;78:13278–84. [pmid: 15542678]
64. Lesburg, CA. Cable, MB. Ferrari, E. Hong, Z. Mannarino, AF. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active siteNat Struct Biol 1999;6:937–43. [pmid: 10504728]
65. Ahlquist, P. Noueiry, AO. Lee, WM. Kushner, DB. Dye, BT. Host factors in positive-strand RNA virus genome replicationJ Virol 2003;77:8181–6. [pmid: 12857886]
66. Ye, J. Wang, C. Sumpter, RJr. Brown, MS. Goldstein, JL. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylationProc Natl Acad Sci U S A 2003;100:15865–70. [pmid: 14668447]
67. Kapadia, SB. Chisari, FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acidsProc Natl Acad Sci U S A 2005;102:2561–6. [pmid: 15699349]
68. You, S. Stump, DD. Branch, AD. Rice, CM. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replicationJ Virol 2004;78:1352–66. [pmid: 14722290]
69. Friebe, P. Boudet, J. Simorre, JP. Bartenschlager, R. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replicationJ Virol 2005;79:380–92. [pmid: 15596831]
70. Wang, C. Gale, MJr. Keller, BC. Huang, H. Brown, MS. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replicationMol Cell 2005;18:425–34. [pmid: 15893726]
71. Watashi, K. Ishii, N. Hijikata, M. Inoue, D. Murata, T. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymeraseMol Cell 2005;19:111–22. [pmid: 15989969]

Hubert E. Blum, MD, is the chairman of the Department of Gastroenterology and Hepatology, University Hospital Freiburg, Germany. His research focus includes molecular biology and immunology of viral hepatitis B and C as well as basic and clinical aspects of gastrointestinal malignancies, especially hepatocellular and colorectal carcinoma.

Darius Moradpour, MD, was Assistant Professor of Medicine and Staff Physician at the Department of Gastroenterology and Hepatology, University Hospital Freiburg, Germany. Since 2004 he is the head of the Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland. His scientific work includes the molecular virology and pathogenesis of the hepatitis C virus infection.

Volker Brass, MD, is resident at the Department of Gastroenterology and Hepatology, University Hospital Freiburg, Germany. Together with Hubert E. Blum and Darius Moradpour, he works on the molecular virology of the hepatitis C virus.


[Figure ID: F1]
Figure 1 

Life cycle of HCV. The steps of the viral life cycle are depicted schematically. The topology of HCV structural and nonstructural proteins at the endoplasmic reticulum (ER) membrane is shown. HCV RNA replication occurs in a specific membrane alteration, the membranous web (MW). IRES-mediated translation and polyprotein processing as well as membranous web formation and RNA replication, illustrated here as separate steps for simplicity, may occur in a tightly coupled manner

[Figure ID: F2]
Figure 2 

Comparison of different replicon systems. A selection of different bicistronic and monocistronic replicon constructs including subgenomic and full-length HCV sequences is depicted schematically. Stably replicating systems are equipped among others with a neomycin phosphotransferase or a hygromycin phosphotransferase cassette that allow selection of cells with continuous RNA replication. Transient systems include a marker gene that allows quantification 48 h after transient transfection. In general, luciferase (Luc) is used as easily quantifiable enzyme in this context and values are normalized based on the amount of input RNA. Monocistronic replicon constructs avoid the translation of proteins from the heterologous encephalomyocarditis virus (EMCV) IRES. The resistance gene is released after cleavage via a ubiquitin sequence (Ubi)

[TableWrap ID: T1] Table 1 

In vitro and in vivo models to study HCV

Article Categories:
  • Review

Keywords: helicase, hepatitis C virus, protease, polymerase, replicon.

Previous Document:  A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) i...
Next Document:  Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease.